| Bid Price | 8.50p | High Price | 9.50p |
|---|
| Ask Price | 9.50p | Low Price | 8.50p |
|---|
| Open Price | 9.25p | Spread | 10.53% |
|---|
| Prev Close | 9.00p | Volume | 263,519 |
|---|
Ondine Biomedical Inc. Historic Prices
| Date | Open | High | Low | Close | Volume |
|---|
| Apr 9, 2025 | 9.00 | 9.11 | 8.50 | 9.00 | 12,003 |
| Apr 8, 2025 | 9.00 | 9.50 | 8.68 | 9.00 | 243,105 |
| Apr 7, 2025 | 9.25 | 9.38 | 8.50 | 8.75 | 170,227 |
| Apr 4, 2025 | 9.25 | 9.30 | 9.00 | 9.25 | 130,636 |
| Apr 3, 2025 | 9.75 | 10.20 | 9.00 | 9.25 | 339,562 |
Ondine Biomedical Inc. Information
| Name | Ondine Biomedical Inc. | Index | FTSE AIM All Share |
|---|
| ISIN | CA68234M2058 | Epic | OBI |
|---|
| Type | Equity | Currency | GBX |
|---|
| Record Status | Active | Trading Segment | ASQ1 |
|---|
| Industry | Biotechnology | Sector | Healthcare |
|---|
| EMS | 20,000 | Trading Status | Post Trading |
|---|
| Shares in Issue | 443.23 m | Prev Close | 9.00p |
|---|
| PE Ratio | | Market Cap | £39.89 m |
|---|
| Div Yield | 0 | Div per Share | NaN CAD |
|---|
| EPS | -0.03 CAD | Div Cover | NaN |
|---|
| PEG | n/a | EPS Growth (%) | 0.00 |
|---|
| ROCE | -5.166889 | DPS Growth (%) | 0 |
|---|
| Current Ratio | 0.804294 | Quick Ratio | 0.363455 |
|---|
Ondine Biomedical Inc. Director Deals
| Declared | Type | Director | Pos. | Volume / Price | Value |
|---|
| 04/02/25 | BUY | Carolyn Cross | CEO | 149,225 @ £0.13 | £18,653.00 |
| 03/02/25 | BUY | Carolyn Cross | CEO | 100,000 @ £0.13 | £12,500.00 |
| 31/01/25 | BUY | Carolyn Cross | CEO | 200,775 @ £0.12 | £24,093.00 |
| 31/01/25 | BUY | Margaret Shaw | NED | 30,000 @ £0.12 | £3,600.00 |
| 22/11/24 | PLAC | Carolyn Cross | CEO | 18,710,100 @ £0.09 | £1,590,359.00 |
| 22/11/24 | PLAC | Margaret Shaw | NED | 197,186 @ £0.09 | £16,761.00 |
| 22/11/24 | PLAC | Junaid Bajwa | NED | 384,920 @ £0.09 | £32,718.00 |
| 22/11/24 | PLAC | Jean Duvall | NED | 419,912 @ £0.09 | £35,693.00 |
| 22/11/24 | PLAC | Michael Farrar | RES | 174,963 @ £0.09 | £14,872.00 |
| 11/11/24 | PLAC | Carolyn Cross | CEO | 1,305,188 @ £0.09 | £110,941.00 |
Ondine Biomedical Inc. News
